Current Trend and Future Prospects of Forging Technology

2008 ◽  
Vol 49 (574) ◽  
pp. 1044-1046
Author(s):  
Takashi ISHIKAWA
Author(s):  
Jean-Yves Berthon ◽  
Thibault Michel ◽  
Aurélie Wauquier ◽  
Pierre Joly ◽  
Jonathan Gerbore ◽  
...  

Abstract Modern agriculture needs proper solutions to face the current trend of pesticides and fertilizers reduction. One of the available leverages to support this transition is the use of bioproducts that are more environmentally friendly and less hazardous for human health. Among them, blue biotechnology and more precisely seaweed and microalgae gain interest every year in the scientific community. In agriculture, seaweeds (Macroalgae) have been used in the production of plant biostimulants while microalgae still remain unexploited. Microalgae are widely described as renewable sources of biofuels, bioingredients and biologically active compounds, such as polyunsaturated fatty acids (PUFAs), carotenoids, phycobiliproteins, sterols, vitamins and polysaccharides, which attract considerable interest in both scientific and industrial communities. They affect agricultural crops for enhancement of plant growth, seedling growth. They can also improve nutrient incorporation, fruit setting, resistance properties against pests and diseases, improving stress management (drought, salinity and temperature). The present review aimed at the interest of blue biotechnology in agronomy, with a specific focus on microalgae, their biological activities and their possible application in agriculture as a potentially sustainable alternative for enhanced crop performance, nutrient uptake and resilience to environmental stress. This review does not only present a comprehensive study of microalgae as plant biostimulants but also as biofertilizers, with a particular emphasis on future challenges these solutions will have to deal with, microalgae being able to synthesize secondary metabolites with potential biopesticidal action.


Swiss Surgery ◽  
1999 ◽  
Vol 5 (3) ◽  
pp. 116-121 ◽  
Author(s):  
Schmassmann

Surgical resection is the first choice of treatment for patients with hepatocellular (HCC) and cholangiocellular carcinomas. Prolongation of survival is, however, the only realistic goal for most patients, which can be often achieved by nonsurgical therapies. Inoperable patients with large or multiple HCCs are usually treated with transarterial chemoembolization (TACE) with lipiodol in combination with a chemotherapeutic drug and gelfoam. Three-year survival depends on the stage of the disease and is about 20%. Patients with earlier tumor stages (one or two tumor nodules less than 3cm in size) are suitable for treatment with percutaneous ethanol injection (PEI) alone or in combination with TACE. Several studies have shown that in these early stages, the 3-year survival rate is approximately 55%-70% in the actively treated patients which is significantly higher than in untreated patients. In advanced stages of the disease, TACE and PEI have no effect on survival and should not be performed. Some of these patients have been successfully treated with octreotide. Patients with inoperable cholangiocellular carcinoma are treated by endoscopic or percutaneous stent placement. If stenting does not achieve adequate biliary drainage, multidisciplinary therapy including internal / external radiotherapy or photodynamic therapy should be considered in patients with potential long-term survival. In conclusion, nonresectional therapies play an essential role in the therapy of inoperable hepato- and cholangiocellular carcinomas as they lead to satisfactory survival. Multidisciplinary therapy appears to be the current trend of management.


Sign in / Sign up

Export Citation Format

Share Document